The pharmaceutical industry is in a period of crisis due to the low number of new drug approvals relative to the high levels of R&D investment. It is argued here that improving the quality of target selection is the single most important factor to transform industry productivity and bring innovative new medicines to patients.
This is a preview of subscription content, log in via an institution to check access.
References
Bernstein Research Pipeline Report, February 2011 (Bernstein, 2011).
Adams, C.P. & Brantner, V.V. Health Econ. 19, 130–141 (2010).
Hopkins, A.L & Groom, C.R. Nat. Rev. Drug Discov. 1, 727–730 (2002).
Edwards, A.M. et al. Nature 470, 163–165 (2011).
Bedford, L. et al. Nat. Rev. Drug Discov. 10, 29–46 (2011).
Cohen, P. & Tcherpakov, M. Cell 143, 686–693 (2010).
Buchwald, P. IUBMB Life 62, 724–731 (2010).
Wells, J.A. & McClendon, C.L. Nature 450, 1001–1009 (2007).
Filippakopoulos, P. et al. Nature 468, 1067–1073 (2010).
Nicodeme, E. et al. Nature 468, 1119–1123 (2010).
De Luca, L. Bioorg. Med. Chem. 18, 7515–7521 (2010).
Kritzer, J.A. Nat. Chem. Biol. 6, 566–567 (2010).
Driggers, E.M. et al. Nat. Rev. Drug Discov. 7, 608–624 (2008).
Bonetta, L. Nature 468, 851–854 (2010).
Venkatesan, K. et al. Nat. Methods 6, 83–90 (2009).
Stumpf, M.P. et al. Proc. Natl. Acad. Sci. USA 105, 6959–6964 (2008).
Metz, J.T. & Hajduk, P.J. Curr. Opin. Chem. Biol. 14, 498–504 (2010).
Nisius, B. & Bajorath, J. Exp. Opin. Drug Discovery 6, 1–7 (2010).
Kromdijk, W. et al. Expert Opin. Pharmacother. 11, 1215–1223 (2010).
Drenth, J.P.H. & Waxman, S.G. J. Clin. Invest. 117, 3603–3609 (2007).
Cockburn, I. & Henderson, R. NBER Working Paper 6018 (National Bureau of Economic Research, Cambridge, Massachusetts, USA, 1997). http://www.nber.org/
Frye, S.V. Nat. Chem. Biol. 6, 159–161 (2010).
Heal, W.P., Dang, T.H.T. & Tate, E.W. Chem. Soc. Rev. 40, 246–257 (2011).
Bunnage, M.E. (ed.) New Frontiers in Chemical Biology: Enabling Drug Discovery (Royal Society of Chemistry Drug Discovery Series, 2011).
Schmid, E.F. & Smith, D.A. Drug Discov. Today 12, 998–1006 (2007).
Bartfai, T. & Lees, G.V. Drug Discovery: From Bedside to Wall Street (Elsevier Academic Press, 2006).
Acknowledgements
The author would like to thank A. Goldsmith, S. Wang, S. Ward and E. Floyd for generating the productivity data shown in Figure 1, as well as the many other colleagues who have also provided input and challenge to the arguments herein.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author is an employee of Pfizer.
Rights and permissions
About this article
Cite this article
Bunnage, M. Getting pharmaceutical R&D back on target. Nat Chem Biol 7, 335–339 (2011). https://doi.org/10.1038/nchembio.581
Published:
Issue Date:
DOI: https://doi.org/10.1038/nchembio.581
- Springer Nature America, Inc.
This article is cited by
-
Concept and application of the probability of pharmacological success (PoPS) as a decision tool in drug development: a position paper
Journal of Translational Medicine (2023)
-
Prioritization and functional validation of target genes from single-cell transcriptomics studies
Communications Biology (2023)
-
Innovation crisis in the pharmaceutical industry? A survey
SN Business & Economics (2021)
-
Peptidomimetics: A Synthetic Tool for Inhibiting Protein–Protein Interactions in Cancer
International Journal of Peptide Research and Therapeutics (2020)
-
Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications
Nature Reviews Drug Discovery (2018)